Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 4, 2024SHILAP Revista de lepidopterologíaOpen Access

Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAnnelieke R. MüllerBHBibiche den HollanderPVPeter M. van de Ven

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Müller et al. (2024) studied this question.

synapsesocial.com/papers/69e2549a34ca36c38e86b82fhttps://doi.org/10.1186/s12888-023-05422-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment2023 · 26 citations
  2. 2Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both2017 · 1,042 citations
  3. 3Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders2014 · 1,007 citations
  4. 4Mucopolysaccharidosis type IIIA: Clinical spectrum and genotype‐phenotype correlations2010 · 196 citations
  5. 5New paradigms for the treatment of lysosomal storage diseases: targeting the endocannabinoid system as a therapeutic strategy2021 · 9 citations